Virpax Pharmaceuticals, Inc. - VRPX STOCK NEWS

Virpax Pharmaceuticals (NASDAQ: VRPX) has secured an extension of its cooperative research agreement with the National Center for Advancing Translational Sciences (NCATS) for developing NES100, an intranasal peptide for acute and chronic non-cancer pain management. NES100 uses nanotechnology to deliver enkephalin, a natural peptide, to the brain via a nasal route. The technology aims to suppress pain by binding to delta opioid receptors without the adverse effects typically associated with opioids, such as tolerance, withdrawal, respiratory depression, euphoria, or addiction. Animal models have shown promising analgesic potential.

Virpax Pharmaceuticals (VRPX) has closed a $5.0 million public offering of common stock and pre-funded warrants at $0.50 per share. The proceeds will fund the company's ongoing activities, including an IND filing for Probudur™, their proprietary patented injectable local anesthetic liposomal technology for post-operative pain management. Funds will also cover marketing services through IR Agency and general corporate purposes. Spartan Capital Securities acted as the exclusive placement agent for the offering.

Virpax Pharmaceuticals (NASDAQ: VRPX) has announced the pricing of a $5.0 million public offering of common stock and pre-funded warrants at $0.50 per share. The proceeds will fund the company's ongoing activities, including its planned IND filing for ProbudurTM, a proprietary patented injectable local anesthetic liposomal technology for post-operative pain management. The offering, managed by Spartan Capital Securities as exclusive placement agent, is expected to close on November 14, 2024. The offering is conducted under the company's Form S-1 registration statement, which was declared effective by the SEC on November 12, 2024.

Virpax Pharmaceuticals (NASDAQ: VRPX) reported its Q2 2024 financial results and recent developments. Key highlights include:

• Positive results from a pharmacokinetics and safety study for Probudur, their lead asset for pain relief
• Secured $2.8 million from warrant exercises and a $2.5 million loan (repaid) to settle litigation
• Regained Nasdaq compliance for minimum bid price
• Q2 operating loss of $3.5 million, up from $3.1 million in Q2 2023
• R&D expenses increased to $2.0 million, primarily due to Probudur preclinical activities
• G&A expenses decreased to $1.5 million
• Cash balance of $1.9 million as of June 30, 2024

The company remains focused on advancing its product candidates and exploring licensing opportunities.

Virpax Pharmaceuticals (NASDAQ: VRPX), a company focused on developing non-addictive products for pain management, PTSD, CNS disorders, and anti-viral barrier indications, has announced its participation in the Sidoti August Virtual Investor Conference on August 14-15, 2024. CEO Gerald W. Bruce and CFO Vinay Shah will represent the company.

Key points:

• Bruce will present on August 14th at 2:30 PM (ET)
• The presentation will be accessible live via a provided link
• Virpax will host one-on-one meetings with investors on both conference days
• Registration for the event is free and open to all, not to Sidoti clients

This conference provides an opportunity for Virpax to showcase its innovative product pipeline and engage with potential investors.

Virpax Pharmaceuticals (NASDAQ: VRPX), a company focused on developing non-addictive products for pain management, post-traumatic stress disorder, CNS disorders, and anti-viral barrier indications, has regained compliance with Nasdaq's minimum bid price requirement. The company received formal notice from Nasdaq's Listing Qualifications staff confirming this development. To meet the requirement, Virpax's common shares had to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on July 19, 2024. As a result, this listing matter has been resolved, ensuring Virpax's continued presence on the Nasdaq stock exchange.

Virpax Pharmaceuticals announced positive results from a Swine Model pilot study for Probudur, their long-acting pain relief formulation. Probudur, designed for extended pain relief, was tested on four juvenile pigs at 30 mg/kg. The study confirmed a long-term, slow-release profile and showed that Probudur was well-tolerated with no adverse effects. Histopathology at the injection site also indicated good tolerance. CEO Gerald Bruce highlighted the consistent positive results and the aim to file an Investigational New Drug Application by year-end. Probudur aims to reduce opioid use post-surgery by providing prolonged pain relief.

Virpax Pharmaceuticals announced securing a $2.5 million loan from an institutional investor, which facilitated the final payment of its litigation settlement. This loan agreement includes negotiating additional funding to support the development of non-addictive pain management and CNS disorder products.

The company's Board of Directors has been reorganized, reducing its members from eight to seven. Four new members—Judy Su, Gary Herman, Jatinder Dhaliwal, and Katharyn Field—have been appointed, while five existing members have resigned.

CEO Gerald Bruce emphasized that this funding will provide the flexibility needed to advance their programs, with the goal of beginning first-in-human trials in 2025. The announcement follows high interest in Virpax's asset portfolio at the recent BIO meeting in San Diego.

Virpax Pharmaceuticals (NASDAQ: VRPX), a firm developing non-addictive treatments for pain, PTSD, CNS disorders, and viral barriers, will present at the 2024 BIO International Convention in San Diego. CEO Gerald W. Bruce will deliver a corporate presentation on June 3rd at 4:00 p.m. PT in Theater 3. The Virpax team will also host meetings from June 3rd through the 5th. Interested parties can schedule meetings via the BIO International meeting platform or by contacting betsy.brod@affinitygrowth.com.